FY26 revenue rises 17% to Rs. 5,453 crore as US generics business jumps 49% and adjusted EBITDA margin improves to 26% for the quarter
The company secured new accounts, including ACCESS-PVI trial sites, and aims to strengthen global commercialization efforts
The transaction marks a clear portfolio reshuffle for Indoco
Pharma and biotech infrastructure firm targets 25–30% growth as Middle East and Africa emerge as key expansion markets
Our company is prioritising deeper collaborations with CDMOs and biosimilar companies as part of its strategy to expand its footprint across India, Middle East, and Africa region
Deal includes 13 branded generic products across 55+ countries; acquisition expected to strengthen global anti-infective portfolio and expand regulated market presence
Outlines nine priority health tracks spanning TB research, digital health, early warning systems and regulatory cooperation
CDSCO-cleared BSM-5700 series targets ICU, NICU, ER, OR and digital health integration under ABDM
Nature Medicine study delivers strongest real-world evidence yet for India’s indigenous rotavirus vaccine under UIP
Minister highlights scope for domestic manufacturing during his meeting with Dr Niti Pall, President-elect, International Diabetes Federation
Subscribe To Our Newsletter & Stay Updated
_256_275.jpeg)
